Clinical Study of Tenecteplase in Intravenous Thrombolysis for Acute Ischemic Stroke
ZHOU Leile
CHEN Ningbo
MO Faxiao
LI Jianwei
LI Na
Abstract：Objective To compare and analyze the application value of tenecteplase versus alteplase in intravenous thrombolysis for acute ischemic stroke(AIS).Methods A total of 194 AIS patients admitted to Kaiping Central Hos-pital from May 2024 to August 2025 were selected as the study subjects.According to the random number table method,they were divided into an observation group(tenecteplase,n=97)and a control group(alteplase,n=97).Neurological func-tion recovery,clinical efficacy,prognosis,and bleeding events were compared between the two groups.Results Before thrombolysis,there was no significant difference in NIHSS scores between the two groups(P=0.227).After thrombolysis,NIHSS scores in both groups showed a significant decreasing trend over time.At 1h,24h,7d,and 14d after thrombolysis,the NIHSS scores of the observation group were significantly lower than those of the control group(P<0.001).There was no significant difference in the total clinical effective rate between the two groups(P=0.427).At 90 days after thrombolysis,the proportion of patients with favorable prognosis in the observation group was significantly higher than that in the control group(P=0.008).The total incidence of bleeding events in the observation group was significantly lower than that in the control group(P=0.005).Conclusion In intravenous thrombolysis for AIS,tenecteplase has comparable clinical efficacy to alteplase.However,tenecteplase is more conducive to the recovery of neurological function,improves long-term prog-nosis,reduces the risk of bleeding,and demonstrates higher safety.
Keywords：tenecteplaseacute ischemic strokeneurological function
Publication Date：2025-10-25
Online Publishing Date：2026-03-05(First online date of this platform, not the publication date of the document)
Pages：4( 1229-1232 )